Michael May

Michael May

Michael May portrait - Board Member

Michael May


Michael May is President and CEO of the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian, not-for-profit that develops technologies, launches new companies and catalyzes investment in the field of regenerative medicine, including cell and gene therapy. CCRM is now seeking partners and financing for a commercial scale cell and gene therapy facility. Prior to CCRM, Michael was the President, and co-founder, of Rimon Therapeutics Ltd., a Toronto-based tissue engineering company developing novel medical polymers that possess drug-like activity.

Dr. May completed his PhD in Chemical Engineering at the University of Toronto in 1998 as an NSERC Scholar and was awarded the Martin Walmsley Fellowship for Technological Entrepreneurship.

Michael sits on a number of boards and advisory committees including: the Ontario Life Sciences Council; the Board of Biologics Manufacturing Centre (BMC) Inc.; OmniaBio; ARM Foundation for Cell & Gene Medicine; and AgeX Corporation. He is the Chairman of ExCellThera Ltd.

Michael May was elected to the BMC Board of Directors in December 2022 and re-elected in December 2023.